ArticleScience (New York, N.Y.)2025
Macrophage peroxisomes guide alveolar regeneration and limit SARS-CoV-2 tissue sequelae.
Abstract read
In one paragraph
Article in Science (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Alveolar Macrophages: Development, Respiratory Homeostasis, Signal Pathways, Diseases, and Therapeutic Opportunities.MedComm · 2026Review
- Article
- Secreted ORF8 reprograms macrophages to enhance SARS-CoV-2 infection of lung epithelial cells.Science advances · 2026Article
- Organelle Crosstalk and Metabolic Reprogramming in Idiopathic Pulmonary Fibrosis: Mechanisms and Therapeutic Implications.Cell biochemistry and function · 2026Review
- Spatial architecture of immunometabolism: Mitochondrial‑organelle interfaces in immune signaling (Review).International journal of molecular medicine · 2026Review
- An immune-poised state of human bronchial epithelial cells mediates defense against RSV in adults.Nature communications · 2026Article
- Secreted ORF8 reprograms macrophages to enhance SARS-CoV-2 infection of lung epithelial cells.bioRxiv : the preprint server for biology · 2026Article
- Reparative "exosome-ark" for mitochondrial transplantation to reprogram macrophages and disrupt pathogenic crosstalk in pulmonary fibrosis.Materials today. Bio · 2026Article
- Integration of single-cell RNA-sequencing and machine learning identifies GRN and FCER1G as potential peroxisomal targets in influenza pathogenesis.BMC infectious diseases · 2026Article
- Myeloid-derived alveolar-like macrophages are a tractable model to understand the role of ontogeny in alveolar macrophage functionbioRxiv : the preprint server for biology · 2026Article
- Article
- Regenerative therapeutics for chronic obstructive pulmonary disease.Pharmacological reviews · 2026Review
- Spatial and cellular composition of lung fibrosis induced by multi-walled carbon nanotubes.Journal of nanobiotechnology · 2026Article
- Type 2 immune history imprints local training in nerve and airway associated interstitial macrophages (NAMs) for disease tolerance during lethal respiratory viral infection.Research square · 2026Article
- Immune dysregulation triggered by inflammatory cytokines in patients with severe respiratory infections.Respiratory research · 2026Article
- IL-33/ST2 Signaling Protects the Heart by Restraining Inflammation and Parasite Burden duringACS infectious diseases · 2026Article
- Innate immune circuits in acute lung injury: macrophage plasticity, ILC crosstalk, and tissue repair failure.Frontiers in immunology · 2026Review
- Temporal regulation of wnt signaling in alveolar development and regeneration: mechanistic insights and therapeutic advances in chronic lung diseases.Frontiers in cell and developmental biology · 2026Review
- Serum lipidome remodeling in viral pneumonia: from pathophysiology to therapeutics.Frontiers in immunology · 2026Review
- Single-Cell Insights Into Macrophage Subtypes in Pulmonary Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
- Commented on by
Authors and funding
30 authors.
Xiaoqin WeiBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.ORCID 0000-0001-6210-7899
Wei QianBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.ORCID 0009-0000-3843-6510
Harish NarasimhanBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.ORCID 0000-0002-3376-8257
Ting ChanBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.ORCID 0009-0008-4413-2108
Xue LiuWomen's Guild Lung Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-2104-9335
Mohd ArishBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.ORCID 0000-0003-4933-5808
Samuel YoungBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.ORCID 0009-0008-9124-9827
Chaofan LiBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.ORCID 0000-0002-5426-1498
In Su CheonBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.ORCID 0000-0001-5160-7783
Qing YuBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.
Gislane Almeida-SantosBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.ORCID 0000-0002-9605-2061
Xiao-Yu ZhaoBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.ORCID 0000-0001-5095-7212
Eric V YeattsBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.ORCID 0009-0005-3347-5402
Olivia J SpearBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.
Megan YiBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.
Tanyalak ParimonWomen's Guild Lung Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-4790-0730
Yinshan FangColumbia Center for Human Development, Department of Medicine, Columbia University Medical Center, New York, NY, USA.ORCID 0000-0001-9249-4498
Young S HahnBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.ORCID 0000-0002-2698-9844
Timothy N J BullockBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.ORCID 0000-0001-6141-3261
Lindsay A SomervilleDivision of Pulmonary Medicine and Critical Care Medicine, Department of Medicine, University of Virginia, Charlottesville, VA, USA.ORCID 0000-0001-7052-0640
Mark H KaplanDepartment of Microbiology and Immunology, Indiana University of School of Medicine, Indianapolis, IN, USA.ORCID 0000-0002-2923-8245
Anne I SperlingDivision of Pulmonary Medicine and Critical Care Medicine, Department of Medicine, University of Virginia, Charlottesville, VA, USA.ORCID 0000-0002-4265-9212
Yun Michael ShimDivision of Pulmonary Medicine and Critical Care Medicine, Department of Medicine, University of Virginia, Charlottesville, VA, USA.ORCID 0000-0002-3780-3371
Robert VassalloDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-2328-0255
Peter ChenWomen's Guild Lung Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-5330-1718
Sarah E EwaldBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.ORCID 0000-0002-5327-7578
Anja C RodenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-8948-4758
Jianwen QueColumbia Center for Human Development, Department of Medicine, Columbia University Medical Center, New York, NY, USA.ORCID 0000-0002-6540-6701
Dianhua JiangWomen's Guild Lung Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-4508-3829
Jie SunBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.ORCID 0000-0002-2347-4511
Funding
Role of Surfactant Proteins in Mediating Noninfectious Inflammatory and FibroproP01HL108793 · NHLBI · DUKE UNIVERSITY · PI JIANG, DIANHUA · 2012 to 2022
$21.3MINTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007496 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Michael G. Brown, Coleen A McNamara · 1995 to 2026
$10.2MHost cellular network governing the development of post SARS-CoV-2 tissue sequelaeR01AI147394 · NIAID · UNIVERSITY OF VIRGINIA · PI Jie Sun · 2020 to 2026
$4.7MMolecular regulation of protective CD8 immunity against influenza infectionR01AI112844 · NIAID · UNIVERSITY OF VIRGINIA · PI SUN, JIE · 2015 to 2024
$4.5MHyperpolarized Xenon-129 MRI: a new multi-dimensional biomarker to determine pulmonary physiologic responses to COPD therapeuticsR01HL132177 · NHLBI · UNIVERSITY OF VIRGINIA · PI QING, KUN, SHIM, YUN MICHAEL · 2017 to 2021
$3.9MElucidating the roles of alveolar macrophage inflammation and selfrenewal during influenza infectionR01AG069264 · NIA · UNIVERSITY OF VIRGINIA · PI Jie Sun · 2020 to 2026
$3.5MSexual dimorphism in susceptibility to emphysematous tissue injuryR01HL167202 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI ANI Wang MANICHAIKUL, Yun Michael Shim · 2023 to 2026
$3.0MRoles of tissue-resident helper T cells in mucosal immunity against influenzainfectionR01AI154598 · NIAID · UNIVERSITY OF VIRGINIA · PI SUN, JIE · 2020 to 2024
$2.9MDeterminants of Convalescent and Vaccine-induced Mucosal Specific Immunity to SARS-CoV-2 and Variants of Concern in Children with AsthmaR01AI176171 · NIAID · UNIVERSITY OF VIRGINIA · PI Jie Sun, WILLIAM GERALD TEAGUE · 2023 to 2026
$2.7MUncover mechanisms underlying the development of chronic lung sequelae post COVID-19R01HL170961 · NHLBI · UNIVERSITY OF VIRGINIA · PI Jie Sun, ROBERT VASSALLO · 2023 to 2026
$2.7MSyndecan-1 suppression of lung inflammation - Diversity SupplementR01HL159953 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHEN, PETER · 2022 to 2025
$2.7MDiscovery of New Anti-Inflammatory Agents to Treat COPDR01HL132287 · NHLBI · GEORGE MASON UNIVERSITY · PI NOBLE, SCHROEDER M, PAIGE, MIKELL · 2016 to 2019
$2.4MNHLBI NIH HHS F31 HL170746NHLBI NIH HHS K08 HL141590NHLBI NIH HHS P01 HL108793NHLBI NIH HHS R01 HL132177NHLBI NIH HHS R01 HL132287NHLBI NIH HHS R01 HL152293NHLBI NIH HHS R01 HL155759NHLBI NIH HHS R01 HL159675NHLBI NIH HHS R01 HL159953NHLBI NIH HHS R01 HL167202NHLBI NIH HHS R01 HL170961NHLBI NIH HHS R01 HL172990NIAID NIH HHS R01 AI112844NIAID NIH HHS R01 AI147394NIAID NIH HHS R01 AI154598NIAID NIH HHS R01 AI176171NIAID NIH HHS R21 AI163753NIAID NIH HHS T32 AI007496NIA NIH HHS R01 AG069264NIDDK NIH HHS R01 DK122737
Abstract
Peroxisomes are vital but often overlooked metabolic organelles. We found that excessive interferon signaling remodeled macrophage peroxisomes. This loss of peroxisomes impaired inflammation resolution and lung repair during severe respiratory viral infections. Peroxisomes were found to modulate lipid metabolism and mitochondrial health in a macrophage type-specific manner and enhanced alveolar macrophage-mediated tissue repair and alveolar regeneration after viral infection. Peroxisomes also prevented excessive macrophage inflammasome activation and IL-1β release, limiting accumulation of KRT8
Indexed as
COVID-19Macrophages, AlveolarPeroxisomesPulmonary AlveoliRegenerationSARS-CoV-2AnimalsHumansInflammasomesInterferonsInterleukin-1betaLipid MetabolismLungMiceMice, Inbred C57BLMitochondriaInflammasomesInterferonsInterleukin-1beta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.